Holen Sie sich die Stockscreener-App
0.7311
1.22%
0.0088
Handel nachbörslich:
.74
0.0089
+1.22%
Schlusskurs vom Vortag:
$0.7223
Offen:
$0.74
24-Stunden-Volumen:
86,320
Relative Volume:
0.35
Marktkapitalisierung:
$36.59M
Einnahmen:
$28,000
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-2.014
EPS:
-0.363
Netto-Cashflow:
$-11.36M
1W Leistung:
-1.97%
1M Leistung:
-15.72%
6M Leistung:
-33.54%
1J Leistung:
+43.10%
1-Tages-Spanne:
$0.6866
$0.743
1-Wochen-Bereich:
$0.6866
$0.7979
52-Wochen-Spanne:
$0.38
$1.57
Talphera Inc Stock (TLPH) Company Profile
Firmenname
Talphera Inc
Sektor
Telefon
650-216-3500
Adresse
1850 GATEWAY DRIVE, SAN MATEO
Compare TLPH vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.7311 | 36.15M | 28,000 | -14.36M | -11.36M | -0.363 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2020-07-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-04-24 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-15 | Eingeleitet | Credit Suisse | Outperform |
| 2018-10-23 | Eingeleitet | B. Riley FBR | Buy |
| 2017-10-13 | Herabstufung | Jefferies | Buy → Hold |
| 2017-10-13 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-07-14 | Fortgesetzt | Jefferies | Buy |
| 2016-09-15 | Bestätigt | ROTH Capital | Buy |
| 2016-08-05 | Herabstufung | Stifel | Buy → Hold |
| 2015-10-30 | Hochstufung | Jefferies | Hold → Buy |
| 2015-10-05 | Bestätigt | ROTH Capital | Buy |
| 2015-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-10 | Fortgesetzt | ROTH Capital | Buy |
| 2015-05-06 | Bestätigt | Mizuho | Neutral |
| 2015-05-05 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-09 | Herabstufung | Mizuho | Buy → Neutral |
Alle ansehen
Talphera Inc Aktie (TLPH) Neueste Nachrichten
Risk Recap: Will Talphera Inc stock hit new highs in YEAR - baoquankhu1.vn
TALPHERA (TLPH) CEO uses 9,938 shares to cover RSU tax withholding - Stock Titan
Talphera (TLPH) CFO surrenders shares to cover RSU tax bill - Stock Titan
TALPHERA, INC. (TLPH) CMO surrenders 2,118 shares for RSU taxes - Stock Titan
[Form 4] TALPHERA, INC. Insider Trading Activity - Stock Titan
[EFFECT] TALPHERA, INC. SEC Filing - Stock Titan
Trend Recap: Does Talphera Inc stock reflect fundamentalsMarket Growth Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Talphera (NASDAQ: TLPH) registers resale of 639,931 shares and 6.4M warrant shares - Stock Titan
Will Talphera Inc benefit from current market trends2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Rate Cut: Why is Talphera Inc stock going down2026 Institutional Moves & Weekly Watchlist of Top Performers - baoquankhu1.vn
TLPH Should I Buy - Intellectia AI
Fed Meeting: Is Talphera Inc stock overvalued or fairly pricedQuarterly Portfolio Summary & Trade Opportunity Analysis Reports - baoquankhu1.vn
Dow Update: Whats the profit margin of Talphera IncGlobal Markets & Technical Pattern Based Buy Signals - baoquankhu1.vn
Talphera files prospectus for resale of up to 30.9M shares by selling stockholders - MSN
Aug EndMonth: Is Talphera Inc a top pick in the sectorMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn
Angotti buys Talphera (TLPH) shares worth $124,999 By Investing.com - Investing.com Australia
Angotti buys Talphera (TLPH) shares worth $124,999 - Investing.com
Talphera (TLPH) CEO boosts stake with 213,310-share open-market buy - Stock Titan
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 - Bitget
Talphera (TLPH) registers resale of up to 7.04M shares from private placement - stocktitan.net
Talphera (TLPH) Reports Progress in Nafamostat Study and Financi - GuruFocus
Talphera: Q4 Earnings Snapshot - theheraldreview.com
Talphera, Inc. (Formerly AcelRx) 2025 Annual Report: Business Overview, Key Risks, and Regulatory Challenges in Specialty Pharmaceuticals - Minichart
Talphera Q4 2025 & Investor Day Earnings Call Transcript - MarketBeat
Talphera Inc. Q4 & Fiscal 2025 Financial Results: Revenue & Net Loss ReportNews and Statistics - IndexBox
[10-K] TALPHERA, INC. Files Annual Report - Stock Titan
Talphera 2025 10-K: Revenue $0.028M, Net Loss $14.3M - tradingview.com
TLPH: Net loss increased to $14.3M in 2025; urgent capital needs and Nasdaq delisting risk persist - TradingView
Talphera Inc (TLPH) Reports Q4 Earnings - AlphaStreet
Earnings call transcript: Talphera Inc. Q4 2025: Stock Declines Amid Study Delays By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc. Q4 2025: Stock Declines Amid Study Delays - Investing.com India
Talphera, Inc. (NASDAQ: TLPH) 2026 Financial Results and Company Information Overview - Minichart
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - MarketScreener
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Talphera: Fourth Quarter Financial Results Overview - Bitget
TLPH: 50% enrollment milestone reached in NEPHRO CRRT study; $20.4M cash at year-end 2025 - TradingView
Rate Hike: Can Talphera Inc grow without external fundingTake Profit & Comprehensive Market Scan Reports - baoquankhu1.vn
Talphera, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TLPH PE Ratio & Valuation, Is TLPH Overvalued - Intellectia AI
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Street Watch: Can Talphera Inc keep up with sector leaders2026 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 - ChartMill
Nantahala Capital-linked holders in Talphera (TLPH) acquire 4,266,211 pre-funded warrants - Stock Titan
Talphera, Inc. (formerly AcelRx Pharmaceuticals) Files Form 8-K – Company Details and SEC Filing Information - Minichart
Talphera (NASDAQ: TLPH) adds $4.1M in third private placement - Stock Titan
Talphera Receives Nasdaq Notice on Minimum Bid Price - The Globe and Mail
Talphera, Inc. 8-K SEC Filing: Company Information, Address, NASDAQ Listing & Key Details (March 11, 2026) - Minichart
Talphera Received Notice of Noncompliance - TradingView
Talphera (NASDAQ: TLPH) faces Nasdaq minimum bid-price deficiency notice - Stock Titan
Finanzdaten der Talphera Inc-Aktie (TLPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Talphera Inc-Aktie (TLPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Feb 12 '26 |
Buy |
0.81 |
105,364 |
85,587 |
586,954 |
| Aslam Shakil | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.81 |
35,000 |
28,430 |
83,178 |
| Dasu Badri N | Chief Engineering Officer |
Feb 12 '26 |
Buy |
0.81 |
35,000 |
28,430 |
76,230 |
| ASADORIAN RAFFI | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.81 |
45,000 |
36,554 |
91,256 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):